Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Research Report 2025
Description
Summary
According to APO Research, The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Post-Polycythemia Vera Myelofibrosis (PPV-MF) include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Post-Polycythemia Vera Myelofibrosis (PPV-MF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post-Polycythemia Vera Myelofibrosis (PPV-MF).
The Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Company
Novartis AG
Merck & Co Inc
AbbVie Inc
Sun Pharma Advanced Research Company Ltd
Promedior Inc
NS Pharma Inc
MEI Pharma Inc
MedImmune LLC
JW Pharmaceutical Corp
Italfarmaco SpA
Incyte Corp
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
CTI BioPharma Corp
Celgene Corp
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type
Idelalisib
Givinostat
Glasdegib
Durvalumab
IMG-7289
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application
Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application
Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Post-Polycythemia Vera Myelofibrosis (PPV-MF) include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Post-Polycythemia Vera Myelofibrosis (PPV-MF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post-Polycythemia Vera Myelofibrosis (PPV-MF).
The Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Company
Novartis AG
Merck & Co Inc
AbbVie Inc
Sun Pharma Advanced Research Company Ltd
Promedior Inc
NS Pharma Inc
MEI Pharma Inc
MedImmune LLC
JW Pharmaceutical Corp
Italfarmaco SpA
Incyte Corp
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
CTI BioPharma Corp
Celgene Corp
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type
Idelalisib
Givinostat
Glasdegib
Durvalumab
IMG-7289
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application
Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application
Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
127 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Idelalisib
- 2.2.3 Givinostat
- 2.2.4 Glasdegib
- 2.2.5 Durvalumab
- 2.2.6 IMG-7289
- 2.2.7 Others
- 2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
- 3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Breakdown Data by Type
- 3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Type (2020-2025)
- 3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Type (2026-2031)
- 4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Breakdown Data by Application
- 4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Application (2020-2025)
- 4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Perspective (2020-2031)
- 5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Growth Trends by Region
- 5.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Region (2020-2025)
- 5.2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Region (2026-2031)
- 5.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Dynamics
- 5.3.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
- 5.3.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Drivers
- 5.3.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Challenges
- 5.3.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue
- 6.1.1 Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue (2020-2025)
- 6.1.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2020-2025)
- 6.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Post-Polycythemia Vera Myelofibrosis (PPV-MF) Head Office and Area Served
- 6.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application
- 6.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Manufacturers Established Date
- 6.6 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
- 7.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
- 7.4 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
- 8.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
- 8.4 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
- 9.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
- 10.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
- 10.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
- 11.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Merck & Co Inc
- 12.2.1 Merck & Co Inc Company Information
- 12.2.2 Merck & Co Inc Business Overview
- 12.2.3 Merck & Co Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.2.5 Merck & Co Inc Recent Developments
- 12.3 AbbVie Inc
- 12.3.1 AbbVie Inc Company Information
- 12.3.2 AbbVie Inc Business Overview
- 12.3.3 AbbVie Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.3.5 AbbVie Inc Recent Developments
- 12.4 Sun Pharma Advanced Research Company Ltd
- 12.4.1 Sun Pharma Advanced Research Company Ltd Company Information
- 12.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
- 12.4.3 Sun Pharma Advanced Research Company Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
- 12.5 Promedior Inc
- 12.5.1 Promedior Inc Company Information
- 12.5.2 Promedior Inc Business Overview
- 12.5.3 Promedior Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.5.5 Promedior Inc Recent Developments
- 12.6 NS Pharma Inc
- 12.6.1 NS Pharma Inc Company Information
- 12.6.2 NS Pharma Inc Business Overview
- 12.6.3 NS Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.6.5 NS Pharma Inc Recent Developments
- 12.7 MEI Pharma Inc
- 12.7.1 MEI Pharma Inc Company Information
- 12.7.2 MEI Pharma Inc Business Overview
- 12.7.3 MEI Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.7.5 MEI Pharma Inc Recent Developments
- 12.8 MedImmune LLC
- 12.8.1 MedImmune LLC Company Information
- 12.8.2 MedImmune LLC Business Overview
- 12.8.3 MedImmune LLC Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.8.5 MedImmune LLC Recent Developments
- 12.9 JW Pharmaceutical Corp
- 12.9.1 JW Pharmaceutical Corp Company Information
- 12.9.2 JW Pharmaceutical Corp Business Overview
- 12.9.3 JW Pharmaceutical Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.9.5 JW Pharmaceutical Corp Recent Developments
- 12.10 Italfarmaco SpA
- 12.10.1 Italfarmaco SpA Company Information
- 12.10.2 Italfarmaco SpA Business Overview
- 12.10.3 Italfarmaco SpA Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.10.5 Italfarmaco SpA Recent Developments
- 12.11 Incyte Corp
- 12.11.1 Incyte Corp Company Information
- 12.11.2 Incyte Corp Business Overview
- 12.11.3 Incyte Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.11.5 Incyte Corp Recent Developments
- 12.12 Gilead Sciences Inc
- 12.12.1 Gilead Sciences Inc Company Information
- 12.12.2 Gilead Sciences Inc Business Overview
- 12.12.3 Gilead Sciences Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.12.5 Gilead Sciences Inc Recent Developments
- 12.13 F. Hoffmann-La Roche Ltd
- 12.13.1 F. Hoffmann-La Roche Ltd Company Information
- 12.13.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.13.3 F. Hoffmann-La Roche Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.13.5 F. Hoffmann-La Roche Ltd Recent Developments
- 12.14 CTI BioPharma Corp
- 12.14.1 CTI BioPharma Corp Company Information
- 12.14.2 CTI BioPharma Corp Business Overview
- 12.14.3 CTI BioPharma Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.14.5 CTI BioPharma Corp Recent Developments
- 12.15 Celgene Corp
- 12.15.1 Celgene Corp Company Information
- 12.15.2 Celgene Corp Business Overview
- 12.15.3 Celgene Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- 12.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.15.5 Celgene Corp Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type (2020-2025) & (US$ Million)
- Table 6. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2020-2025)
- Table 7. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Type (2026-2031) & (US$ Million)
- Table 8. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2026-2031)
- Table 9. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application (2020-2025) & (US$ Million)
- Table 10. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2020-2025)
- Table 11. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Application (2026-2031) & (US$ Million)
- Table 12. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2026-2031)
- Table 13. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 14. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2020-2025) & (US$ Million)
- Table 15. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region (2020-2025)
- Table 16. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Region (2026-2031) & (US$ Million)
- Table 17. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region (2026-2031)
- Table 18. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
- Table 19. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers
- Table 20. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges
- Table 21. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
- Table 22. Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue (US$ Million) & (2020-2025)
- Table 23. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2020-2025)
- Table 24. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Players Ranking, 2023 VS 2024 VS 2025
- Table 25. Global Key Players of Post-Polycythemia Vera Myelofibrosis (PPV-MF), Headquarters and Area Served
- Table 26. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application
- Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 29. Players Mergers & Acquisitions, Expansion Plans
- Table 30. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 31. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
- Table 32. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
- Table 33. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 34. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
- Table 35. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
- Table 36. Asia Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 37. Asia Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2020-2025) & (US$ Million)
- Table 38. Asia Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
- Table 39. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 40. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
- Table 41. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
- Table 42. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 43. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
- Table 44. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
- Table 45. Novartis AG Company Information
- Table 46. Novartis AG Business Overview
- Table 47. Novartis AG Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 48. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 49. Novartis AG Recent Developments
- Table 50. Merck & Co Inc Company Information
- Table 51. Merck & Co Inc Business Overview
- Table 52. Merck & Co Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 53. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 54. Merck & Co Inc Recent Developments
- Table 55. AbbVie Inc Company Information
- Table 56. AbbVie Inc Business Overview
- Table 57. AbbVie Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 58. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 59. AbbVie Inc Recent Developments
- Table 60. Sun Pharma Advanced Research Company Ltd Company Information
- Table 61. Sun Pharma Advanced Research Company Ltd Business Overview
- Table 62. Sun Pharma Advanced Research Company Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 63. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 64. Sun Pharma Advanced Research Company Ltd Recent Developments
- Table 65. Promedior Inc Company Information
- Table 66. Promedior Inc Business Overview
- Table 67. Promedior Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 68. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 69. Promedior Inc Recent Developments
- Table 70. NS Pharma Inc Company Information
- Table 71. NS Pharma Inc Business Overview
- Table 72. NS Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 73. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 74. NS Pharma Inc Recent Developments
- Table 75. MEI Pharma Inc Company Information
- Table 76. MEI Pharma Inc Business Overview
- Table 77. MEI Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 78. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 79. MEI Pharma Inc Recent Developments
- Table 80. MedImmune LLC Company Information
- Table 81. MedImmune LLC Business Overview
- Table 82. MedImmune LLC Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 83. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 84. MedImmune LLC Recent Developments
- Table 85. JW Pharmaceutical Corp Company Information
- Table 86. JW Pharmaceutical Corp Business Overview
- Table 87. JW Pharmaceutical Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 88. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 89. JW Pharmaceutical Corp Recent Developments
- Table 90. Italfarmaco SpA Company Information
- Table 91. Italfarmaco SpA Business Overview
- Table 92. Italfarmaco SpA Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 93. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 94. Italfarmaco SpA Recent Developments
- Table 95. Incyte Corp Company Information
- Table 96. Incyte Corp Business Overview
- Table 97. Incyte Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 98. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 99. Incyte Corp Recent Developments
- Table 100. Gilead Sciences Inc Company Information
- Table 101. Gilead Sciences Inc Business Overview
- Table 102. Gilead Sciences Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 103. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 104. Gilead Sciences Inc Recent Developments
- Table 105. F. Hoffmann-La Roche Ltd Company Information
- Table 106. F. Hoffmann-La Roche Ltd Business Overview
- Table 107. F. Hoffmann-La Roche Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 108. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 109. F. Hoffmann-La Roche Ltd Recent Developments
- Table 110. CTI BioPharma Corp Company Information
- Table 111. CTI BioPharma Corp Business Overview
- Table 112. CTI BioPharma Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 113. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 114. CTI BioPharma Corp Recent Developments
- Table 115. Celgene Corp Company Information
- Table 116. Celgene Corp Business Overview
- Table 117. Celgene Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
- Table 118. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- Table 119. Celgene Corp Recent Developments
- Table 120. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Image
- Figure 5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Comparison by Type (2025-2031) & (US$ Million)
- Figure 6. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Type: 2024 VS 2031
- Figure 7. Idelalisib Product
- Figure 8. Givinostat Product
- Figure 9. Glasdegib Product
- Figure 10. Durvalumab Product
- Figure 11. IMG-7289 Product
- Figure 12. Others Product
- Figure 13. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application (2025-2031) & (US$ Million)
- Figure 14. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Application: 2024 VS 2031
- Figure 15. Hospital Product
- Figure 16. Clinic Product
- Figure 17. Others Product
- Figure 18. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (US$ Million), Year-over-Year: 2020-2031
- Figure 19. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size, (US$ Million), 2020 VS 2024 VS 2031
- Figure 20. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region: 2024 VS 2031
- Figure 21. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Players in 2024
- Figure 22. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Manufacturers Established Date
- Figure 23. Global Top 5 and 10 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Market Share by Revenue in 2024
- Figure 24. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 25. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 26. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
- Figure 27. United States Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 28. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 29. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
- Figure 30. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 31. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
- Figure 32. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 33. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 34. U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 35. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 36. Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 37. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 38. Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 39. Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 40. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 41. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
- Figure 42. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 43. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 44. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 45. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 46. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
- Figure 47. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 48. China Taiwan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 50. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 51. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
- Figure 52. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 53. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 54. Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 55. Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 56. Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 57. Novartis AG Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 58. Merck & Co Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 59. AbbVie Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 60. Sun Pharma Advanced Research Company Ltd Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 61. Promedior Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 62. NS Pharma Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 63. MEI Pharma Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 64. MedImmune LLC Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 65. JW Pharmaceutical Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 66. Italfarmaco SpA Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 67. Incyte Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 68. Gilead Sciences Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 69. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 70. CTI BioPharma Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
- Figure 71. Celgene Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


